Immunopathological effects of Agaricus blazei Murill polysaccharides against Schistosoma mansoni infection by Th1 and NK1 cells differentiation

Ming Hong Lin, Kin Mu Lee, Che Yuan Hsu, Shih Yi Peng, Ching Nan Lin, Chin Chu Chen, Chia Kwung Fan, Po Ching Cheng

Research output: Contribution to journalArticle

Abstract

In this study, we examined the ability of A. blazei Murill polysaccharides (AB-PS) to activate the immune system in vivo and the protective activity exhibited against parasitic S. mansoni in the murine model. AB-PS treatment significantly reduced the worm and egg burden in infected BALB/c and C57BL/6 mice with dose- and time-dependent manners. Additionally, a dose- and time-dependent expression of IL-2, INF-γ, and TNF-α cytokines was also observed in both strains of mice treatments. Using T1/T2 doubly transgenic mice, we demonstrated that AB-PS-treated mice splenocytes initiated early differentiation of Th1 and NK1 cells, which was consistent with the reduction course of Schistosoma infection. Although AB-PS treatment enhanced the Th1 response, it did not suppress Th2 cell activity in treated mice. Histopathological data of the livers showed AB-PS treatment significantly attenuated the liver fibrosis induced by S. mansoni eggs. AB-PS augmented type-1 responses by inducing Th1 and NK1 cell differentiation to effectively decrease the infection rate of S. mansoni. Furthermore, AB-PS treatment may not only inhibit the schistosome infection, but also improving the pathological effects of granulomas formation. This study provides evidence for a novel therapeutic potential, by which A. blazei Murill may be used to treat or prevent schistosome infection.

Original languageEnglish
Pages (from-to)502-514
Number of pages13
JournalInternational Immunopharmacology
Volume73
DOIs
Publication statusPublished - Aug 1 2019

Fingerprint

Agaricus
Schistosomiasis mansoni
Th1 Cells
Polysaccharides
Cell Differentiation
Schistosoma mansoni
Infection
Schistosoma
Th2 Cells
Granuloma
Inbred C57BL Mouse
Liver Cirrhosis
Eggs
Transgenic Mice
Interleukin-2
Ovum
Immune System
Cytokines
Liver

Keywords

  • Agaricus blazei Murill polysaccharides
  • Immunomodulation
  • NK cell
  • Schistosoma mansoni
  • T1/T2 doubly transgenic mice

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

Immunopathological effects of Agaricus blazei Murill polysaccharides against Schistosoma mansoni infection by Th1 and NK1 cells differentiation. / Lin, Ming Hong; Lee, Kin Mu; Hsu, Che Yuan; Peng, Shih Yi; Lin, Ching Nan; Chen, Chin Chu; Fan, Chia Kwung; Cheng, Po Ching.

In: International Immunopharmacology, Vol. 73, 01.08.2019, p. 502-514.

Research output: Contribution to journalArticle

@article{f485cc97a12c42d29a608efa6f9e110b,
title = "Immunopathological effects of Agaricus blazei Murill polysaccharides against Schistosoma mansoni infection by Th1 and NK1 cells differentiation",
abstract = "In this study, we examined the ability of A. blazei Murill polysaccharides (AB-PS) to activate the immune system in vivo and the protective activity exhibited against parasitic S. mansoni in the murine model. AB-PS treatment significantly reduced the worm and egg burden in infected BALB/c and C57BL/6 mice with dose- and time-dependent manners. Additionally, a dose- and time-dependent expression of IL-2, INF-γ, and TNF-α cytokines was also observed in both strains of mice treatments. Using T1/T2 doubly transgenic mice, we demonstrated that AB-PS-treated mice splenocytes initiated early differentiation of Th1 and NK1 cells, which was consistent with the reduction course of Schistosoma infection. Although AB-PS treatment enhanced the Th1 response, it did not suppress Th2 cell activity in treated mice. Histopathological data of the livers showed AB-PS treatment significantly attenuated the liver fibrosis induced by S. mansoni eggs. AB-PS augmented type-1 responses by inducing Th1 and NK1 cell differentiation to effectively decrease the infection rate of S. mansoni. Furthermore, AB-PS treatment may not only inhibit the schistosome infection, but also improving the pathological effects of granulomas formation. This study provides evidence for a novel therapeutic potential, by which A. blazei Murill may be used to treat or prevent schistosome infection.",
keywords = "Agaricus blazei Murill polysaccharides, Immunomodulation, NK cell, Schistosoma mansoni, T1/T2 doubly transgenic mice",
author = "Lin, {Ming Hong} and Lee, {Kin Mu} and Hsu, {Che Yuan} and Peng, {Shih Yi} and Lin, {Ching Nan} and Chen, {Chin Chu} and Fan, {Chia Kwung} and Cheng, {Po Ching}",
year = "2019",
month = "8",
day = "1",
doi = "10.1016/j.intimp.2019.05.045",
language = "English",
volume = "73",
pages = "502--514",
journal = "International Immunopharmacology",
issn = "1567-5769",
publisher = "Elsevier",

}

TY - JOUR

T1 - Immunopathological effects of Agaricus blazei Murill polysaccharides against Schistosoma mansoni infection by Th1 and NK1 cells differentiation

AU - Lin, Ming Hong

AU - Lee, Kin Mu

AU - Hsu, Che Yuan

AU - Peng, Shih Yi

AU - Lin, Ching Nan

AU - Chen, Chin Chu

AU - Fan, Chia Kwung

AU - Cheng, Po Ching

PY - 2019/8/1

Y1 - 2019/8/1

N2 - In this study, we examined the ability of A. blazei Murill polysaccharides (AB-PS) to activate the immune system in vivo and the protective activity exhibited against parasitic S. mansoni in the murine model. AB-PS treatment significantly reduced the worm and egg burden in infected BALB/c and C57BL/6 mice with dose- and time-dependent manners. Additionally, a dose- and time-dependent expression of IL-2, INF-γ, and TNF-α cytokines was also observed in both strains of mice treatments. Using T1/T2 doubly transgenic mice, we demonstrated that AB-PS-treated mice splenocytes initiated early differentiation of Th1 and NK1 cells, which was consistent with the reduction course of Schistosoma infection. Although AB-PS treatment enhanced the Th1 response, it did not suppress Th2 cell activity in treated mice. Histopathological data of the livers showed AB-PS treatment significantly attenuated the liver fibrosis induced by S. mansoni eggs. AB-PS augmented type-1 responses by inducing Th1 and NK1 cell differentiation to effectively decrease the infection rate of S. mansoni. Furthermore, AB-PS treatment may not only inhibit the schistosome infection, but also improving the pathological effects of granulomas formation. This study provides evidence for a novel therapeutic potential, by which A. blazei Murill may be used to treat or prevent schistosome infection.

AB - In this study, we examined the ability of A. blazei Murill polysaccharides (AB-PS) to activate the immune system in vivo and the protective activity exhibited against parasitic S. mansoni in the murine model. AB-PS treatment significantly reduced the worm and egg burden in infected BALB/c and C57BL/6 mice with dose- and time-dependent manners. Additionally, a dose- and time-dependent expression of IL-2, INF-γ, and TNF-α cytokines was also observed in both strains of mice treatments. Using T1/T2 doubly transgenic mice, we demonstrated that AB-PS-treated mice splenocytes initiated early differentiation of Th1 and NK1 cells, which was consistent with the reduction course of Schistosoma infection. Although AB-PS treatment enhanced the Th1 response, it did not suppress Th2 cell activity in treated mice. Histopathological data of the livers showed AB-PS treatment significantly attenuated the liver fibrosis induced by S. mansoni eggs. AB-PS augmented type-1 responses by inducing Th1 and NK1 cell differentiation to effectively decrease the infection rate of S. mansoni. Furthermore, AB-PS treatment may not only inhibit the schistosome infection, but also improving the pathological effects of granulomas formation. This study provides evidence for a novel therapeutic potential, by which A. blazei Murill may be used to treat or prevent schistosome infection.

KW - Agaricus blazei Murill polysaccharides

KW - Immunomodulation

KW - NK cell

KW - Schistosoma mansoni

KW - T1/T2 doubly transgenic mice

UR - http://www.scopus.com/inward/record.url?scp=85066499446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066499446&partnerID=8YFLogxK

U2 - 10.1016/j.intimp.2019.05.045

DO - 10.1016/j.intimp.2019.05.045

M3 - Article

AN - SCOPUS:85066499446

VL - 73

SP - 502

EP - 514

JO - International Immunopharmacology

JF - International Immunopharmacology

SN - 1567-5769

ER -